Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Mouse CD151 Antibody, R&D Systems™

Rat Monoclonal Antibody
Supplier: R&D Systems MAB4609
This item is not returnable.
View return policy
Description
CD151 Monoclonal specifically detects CD151 in Mouse samples. It is validated for Flow Cytometry, Immunocytochemistry, CyTOF-ready.Specifications
CD151 | |
Monoclonal | |
LYOPH | |
Flow Cytometry 0.25 ug/10^6 cells, Immunocytochemistry 8-25 ug/mL, CyTOF-ready | |
BAA22447 | |
CD151 | |
HEK293 human embryonic kidney cell line transfected with mouse CD151 Met1-Tyr253 Accession # BAA22447 | |
100 μg | |
Primary | |
Detects mouse CD151. Stains mouse CD151 transfectants but not irrelevant transfectants. | |
Mouse | |
Purified |
Flow Cytometry, Immunocytochemistry, CyTOF | |
455807 | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
CD151, CD151 antigen (Raph blood group), CD151 antigenplatelet surface glycoprotein gp27, CD151 molecule (Raph blood group), GP27, Membrane glycoprotein SFA-1, MER2, PETA3, PETA-3, PETA-3SFA-1, platelet-endothelial cell tetraspan antigen 3, Platelet-endothelial tetraspan antigen 3, RAPH, SFA1, SFA-1, tetraspanin-24, tspan-24, TSPAN24, TSPAN24hemidesmosomal tetraspanin CD151 | |
Rat | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
977 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG2a |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction